The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo

Erasmus University Rotterdam, Rotterdam, South Holland, Netherlands
Neurobiology of Disease (Impact Factor: 5.08). 04/2006; 21(3):549-55. DOI: 10.1016/j.nbd.2005.08.019
Source: PubMed


The FMR1 gene, mutated in Fragile X syndrome patients, has been modeled in mice with a neomycin cassette inserted in exon 5 of the mouse Fmr1 gene creating an Fmr1 knockout (Fmr1 KO) allele. This results in animals lacking Fmr1 protein (Fmrp) expression in all tissues. We have created a new, more versatile Fmr1 in vivo KO model (Fmr1 KO2) and generated conditional Fmr1 KO (CKO) mice by flanking the promoter and first exon of Fmr1 with lox P sites. This enables us to create a null allele in specific cell types and at specific time points by crossing Fmr1 CKO mice with tissue specific or inducible cre-recombinase expressing mice. The new Fmr1 KO2 line does not express any Fmrp and also lacks detectable Fmr1 transcripts. Crossing the Fmr1 CKO line with a Purkinje cell-specific cre-recombinase expresser produces mice that are null for Fmr1 in Purkinje neurons but wild type in all other cell types.

Download full-text


Available from: Tao Zu, Nov 24, 2015
  • Source
    • "Brain tissue samples were homogenized and stepwise centrifuged to remove cell debris and to extract the synaptosomes, as described by Schrimpf, 2005[12]. Broek, JAC │6 For neuronal cultures, E18 Fmr1 KO(2) and WT mouse embryos with a C57BL/6 background[9]were decapitated and both the hippocampi and the cerebella were dissected and used for neuronal cell culture (as described below). For electron microscopy, Purkinje cell-specific Fmr1 KO mice with a C57BL/6 background were generated via deletion of the first coding exon of Fmr1 through Cre-mediated recombination, as described by Koekkoek and colleagues[13]. "

    Full-text · Article · Dec 2015 · BMC Neuroscience
  • Source
    • "musculus ). Several mouse models have been generated, such as Fmr1 KO, Fmr1 conditional KO, Fmr1 conditional restoration (Bakker et al. 1994; Mientjes et al. 2006), and recently a mouse model for the I304N mutation, Fmr1 I304N (Zang et al. 2009). All these lines are available in different strains, such as A/J, C57Bl/6, 129/Ola, FVB, Balb, DBA, and many more (Paradee et al. 1999; Pietropaolo et al. 2011; Spencer et al. 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fragile X syndrome (FXS) is considered the leading inherited cause of intellectual disability and autism. In FXS, the fragile X mental retardation 1 (FMR1) gene is silenced and the fragile X mental retardation protein (FMRP) is not expressed, resulting in the characteristic features of the syndrome. Despite recent advances in understanding the pathophysiology of FXS, there is still no cure for this condition; current treatment is symptomatic. Preclinical research is essential in the development of potential therapeutic agents. This review provides an overview of the preclinical evidence supporting metabotropic glutamate receptor 5 (mGluR5) antagonists as therapeutic agents for FXS. According to the mGluR theory of FXS, the absence of FMRP leads to enhanced glutamatergic signaling via mGluR5, which leads to increased protein synthesis and defects in synaptic plasticity including enhanced long-term depression. As such, efforts to develop agents that target the underlying pathophysiology of FXS have focused on mGluR5 modulation. Animal models, particularly the Fmr1 knockout mouse model, have become invaluable in exploring therapeutic approaches on an electrophysiological, behavioral, biochemical, and neuroanatomical level. Two direct approaches are currently being investigated for FXS treatment: reactivating the FMR1 gene and compensating for the lack of FMRP. The latter approach has yielded promising results, with mGluR5 antagonists showing efficacy in clinical trials. Targeting mGluR5 is a valid approach for the development of therapeutic agents that target the underlying pathophysiology of FXS. Several compounds are currently in development, with encouraging results.
    Full-text · Article · Nov 2013 · Psychopharmacology
  • Source
    • "All behavioral procedures took place during the animal light cycle. Male fmr1−/− mice on a C57BL/6J genetic background [62] aged 10 to 11 weeks (P70 - 80) (fmr1−/− ) were used, with wild-type littermates used as control group. Mice were genotyped by tail PCR as described by [62]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fear behavior is vital for survival and involves learning contingent associations of non-threatening cues with aversive stimuli. In contrast, excessive levels of fear can be maladaptive and lead to anxiety disorders. Generally, extensive sessions of extinction training correlates with reduced spontaneous recovery. The molecular mechanisms underlying the long-term inhibition of fear recovery following repeated extinction training are not fully understood. Here we show that in rats, prolonged extinction training causes greater reduction in both fear-potentiated startle and spontaneous recovery. This effect was specifically blocked by metabotropic glutamate receptor 5 (mGluR5), but not by mGluR1 antagonists and by a protein synthesis inhibitor. Similar inhibition of memory recovery following prolonged extinction training was also observed in mice. In agreement with the instrumental role of mGluR5 in the prolonged inhibition of fear recovery, we found that FMR1-/- mice which exhibit enhanced mGluR5-mediated signaling exhibit lower spontaneous recovery of fear after extinction training than wild-type littermates. At the molecular level, we discovered that prolonged extinction training reversed the fear conditioning-induced increase in surface expression of GluR1, AMPA/NMDA ratio, postsynaptic density-95 (PSD-95) and synapse-associated protein-97 (SAP97). Accordingly, delivery of Tat-GluR23Y, a synthetic peptide that blocks AMPA receptor endocytosis, inhibited prolonged extinction training-induced inhibition of fear recovery. Together, our results demonstrate that prolonged extinction training results in the mGluR5-dependent long-term inhibition of fear recovery. This effect may involve the degradation of original memory and may explain the beneficial effects of prolonged exposure therapy for the treatment of phobias.
    Full-text · Article · Jun 2013 · PLoS ONE
Show more